Newsroom

Sorted by: Latest

-

Herbalife Announces $250 Million Share Repurchase Program

LOS ANGELES--(BUSINESS WIRE)--Herbalife Ltd. (NYSE: HLF) [“the Company”], a premier health and wellness company, community and platform, today announced its Board of Directors has authorized the repurchase of up to $250 million of the Company’s outstanding common stock over 3 years. The new authorization reflects the Company’s confidence in its business strategy, financial outlook and ability to generate sustainable free cash flow, while providing an additional avenue to create long-term value...
-

First Trust Global Funds PLC UK Regulatory Announcement: Net Asset Value(s)

LONDON--(BUSINESS WIRE)--  Funds Date TIDM ISIN Code Shares in Issue Currency Net Asset Value NAV/per Share First Trust Growth Strength UCITS ETF 07.09.2026 FTGS.LN IE000YZLMXT9   25,002.00 USD    604,922.75   24.195  ...
-

Silicon Data Appoints Syntax Data as Independent Index Calculation Agent, Advancing Institutional Infrastructure for Compute Risk Management

NEW YORK--(BUSINESS WIRE)--Silicon Data, the independent data and transparency layer for the compute economy, and Syntax Data, an institutional index provider and financial data and technology company, today announced that Syntax has been appointed index calculation agent for Silicon Data’s benchmark index family covering GPU and AI infrastructure markets. The appointment brings independent, third-party calculation to a set of benchmarks that increasingly serve as reference rates for a new asse...
-

Definium Therapeutics Receives Breakthrough Therapy Designation for DT120 (lysergide) Orally Disintegrating Tablet (ODT) in Major Depressive Disorder (MDD) Following Positive Phase 3 Results

NEW YORK--(BUSINESS WIRE)--Definium Therapeutics, Inc. (“Definium” or the “Company”), a late-stage clinical biopharmaceutical company developing a new generation of therapeutics intended to address underlying causes of psychiatric and neurological disorders, today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation for DT120 (lysergide) ODT. The designation was supported by the significant unmet medical need in MDD and results from the Company...
-

SEPT. 8-10: Top Cyber Experts from Federal Agencies, Companies, and Allies Share Critical Insights at 17th Annual Billington CyberSecurity Summit in DC

--(BUSINESS WIRE)--Cyber & AI experts from federal agencies and allied nations will explore issues impacting the nation and world at the Billington CyberSecurity Summit....
-

BETA Technologies to Participate in Upcoming Investor Conferences

SOUTH BURLINGTON, Vt.--(BUSINESS WIRE)--BETA Technologies, Inc. (NYSE: BETA) (“BETA” or the “Company”), an aerospace and defense company, today announced its participation at the following upcoming investor conferences: On Thursday, September 10, 2026, Herman Cueto, chief financial officer, and Devon Rothman, head of investor relations and FP&A, will participate in a fireside chat at the Jefferies Global Industrials Conference at 9:30 a.m. ET. The Company will also participate in individual...
-

D-Wave Quantum Finalizes Definitive Agreement with U.S. Department of Commerce for up to $100 Million to Accelerate U.S. Leadership in Quantum Computing

PALO ALTO, Calif.--(BUSINESS WIRE)--D-Wave quantum finalizes a definitive agreement with the U.S. department of commerce for up to $100 million to accelerate U.S. quantum leadership...
-

United Natural Foods, Inc. Reports Fourth Quarter and Full Year Fiscal 2026 Results

PROVIDENCE, R.I.--(BUSINESS WIRE)--United Natural Foods, Inc. (NYSE: UNFI) (the “Company” or “UNFI”) today reported financial results for the fourth quarter (13 weeks) and fiscal year (52 weeks) ended August 1, 2026. Fourth Quarter Fiscal 2026   Full Year Fiscal 2026 Net sales decreased 0.7% to $7.6 billion Net income of $35 million; Net income per diluted share (EPS) of $0.57 Adjusted EBITDA(1) increased 48.3% to $172 million Adjusted EPS(1) increased to $0.69 Net cash provided by operating ac...
-

Solstice Gold Announces Closing of Fully Subscribed Private Placement

VANCOUVER, British Columbia--(BUSINESS WIRE)--Solstice Gold Corp. (TSXV: SGC) (“Solstice”, “we”, “our” or the “Company”) is pleased to report the closing of its previously announced private placement financing on September 4, 2026 for gross proceeds of approximately $650,000 through the issuance of 10,833,333 common shares (“Common Shares”) at a price of $0.06 per Common Share for gross proceeds of $650,000 (the “Private Placement”). The proceeds of the Private Placement will be used and are nec...
-

United Therapeutics Corporation Announces Accelerated Share Repurchase Agreement for Remainder of $2.0 Billion Authorization

SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, announced today that the company will utilize the remainder of its previously announced $2 billion share repurchase authorization. To complete the utilization, United Therapeutics today will enter into an Accelerated Share Repurchase (ASR) agreement with Citibank, N.A. (Citi) to repurchase the company’s common stock, for approximately $477.6 million. T...